• Education
  • |
  • Points
  • Get the app
  • Country
    singapore
    hong kong
    malaysia
    indonesia
    thailand
    philippines
    vietnam
    india

    australia
    korea
    new zealand
The MIMS logo.
  • Home
  • Find Drugs
  • Pill Identifier
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The MIMS logo.
Home Find Drugs Pill Identifier Find Drug Company Diseases Medical News & Updates
Other Services
MIMS Education MIMS Points Download App
Country
  • a globesingapore
  • a globehong kong
  • a globeindonesia
  • a globethailand
  • a globephilippines
  • a globevietnam
  • a globeindia
  • a globeaustralia
  • a globekorea
  • a globenew zealand
The MIMS logo.
Molecular structure pattern
  1. Home icon
  2. Diseases
  3. Gestational Diabetes Mellitus
    • Diseases
    • Gestational Diabetes Mellitus
  4. Follow Up

Gestational Diabetes Mellitus Follow Up

Last updated: 13 May 2026
Reviewed by
PAGINATION TESTMIMS Obstetrics & Gynecology Honorary Editorial Advisory Board
Follow Up
Monitoring
OverviewHistory and Physical ExaminationDiagnosisManagement
IntroductionEpidemiologyPathophysiologyRisk Factors
Clinical PresentationHistoryPhysical ExaminationDiagnosis or Diagnostic CriteriaScreening
Differential Diagnosis
EvaluationNonpharmacologicalPharmacological therapy
Monitoring
Insulin PreparationsDisclaimerRelated MIMS Drugs
OverviewHistory and Physical ExaminationDiagnosisManagement
IntroductionEpidemiologyPathophysiologyRisk Factors
Clinical PresentationHistoryPhysical ExaminationDiagnosis or Diagnostic CriteriaScreening
Differential Diagnosis
EvaluationNonpharmacologicalPharmacological therapy
Monitoring
Insulin PreparationsDisclaimerRelated MIMS Drugs

Monitoring

Postpartum Management

In addition to routine obstetric care, immediate postpartum management should prioritize glycemic control. Evaluate and adjust Insulin requirements after delivery due to the dramatic decrease in insulin resistance immediately postpartum. All women, including those with gestational diabetes mellitus, are encouraged to exclusively breastfeed. It may decrease offspring obesity and prevent the development of type 2 DM. Except for Metformin and Glibenclamide, other oral hypoglycemic agents should be avoided while breastfeeding. Early feeding of the baby is advised to reduce the risk of neonatal hypoglycemia.

Overweight or obese women with a history of gestational diabetes mellitus who have prediabetes should be offered intensive lifestyle intervention or Metformin to prevent diabetes. Postpartum support for self-care and psychosocial assessment is also recommended to detect the onset of anxiety, depression, stress, and eating disorders. Establish and implement a contraceptive plan for all individuals with diabetes of childbearing potential.

Postpartum Diabetes Mellitus (DM) Screening

All women who will be identified to have overt DM during pregnancy or have gestational diabetes mellitus should have postpartum glucose testing. Women with gestational diabetes mellitus should be screened for persistent DM 4-12 weeks postpartum as the risk of developing maternal type 2 diabetes is increased after pregnancy and because GDM may be an undiagnosed pre-existing type 1 or 2 diabetes. Probability of progression to DM is high with the following postnatal test results: Impaired glucose tolerance with 75-g OGTT, A1c of 5.7-6.4%, and FPG of 5.7-6.9 mmol/L. This uses the 75-g OGTT, fasting plasma glucose test, and non-pregnancy diagnostic criteria. OGTT is more sensitive to detecting glucose intolerance, prediabetes, and diabetes. A1c is not advised for diagnosis of postpartum-persistent diabetes; it may be offered at 1 year postpartum in women with gestational diabetes mellitus who have negative postnatal tests for diabetes. Lifelong screening for development of type 2 DM or prediabetes at least every 1-3 years is recommended for all women with a history of gestational diabetes mellitus, with screening frequency depending on other risk factors.

The MIMS logo.
  • Drugs
  • Find Drugs
  • Pill Identifier
  • Find Drug Company
  • MIMS Abbreviation Index
  • Diseases
  • Search Disease Information
  • Editorial Advisory Board
  • Medical News & Updates
  • Latest News & Updates
  • More Services
  • Education
  • Points
  • Subscribe
  • About
  • MIMS Corporate
  • Terms of Use
  • Privacy Policy
  • Feedback
Connect with MIMS
A social media brand icon.A social media brand icon.
TUV Nord ISO 9001 certification logo
MIMS Specialty release/v3.16.0_3176.1
Copyright © 2026 MIMS Pte Ltd. All rights reserved. UAT
MIMS Logo

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?
Something went wrong.